Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.530
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
2.509
-0.021 (-0.83%)
After-hours: Mar 28, 2025, 7:10 PM EDT

Aerovate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
21.4117.1914.628.040.95
Upgrade
Research & Development
53.1964.2238.6214.997.94
Upgrade
Operating Expenses
74.681.4153.2423.028.89
Upgrade
Operating Income
-74.6-81.41-53.24-23.02-8.89
Upgrade
Interest Expense
-----0.08
Upgrade
Interest & Investment Income
5.045.951.830.07-
Upgrade
Other Non Operating Income (Expenses)
-0.02-0-0.08-0-0
Upgrade
EBT Excluding Unusual Items
-69.57-75.47-51.49-22.96-8.97
Upgrade
Other Unusual Items
-----0.64
Upgrade
Pretax Income
-69.57-75.47-51.49-22.96-9.61
Upgrade
Income Tax Expense
0.060.060.030-
Upgrade
Net Income
-69.63-75.52-51.51-22.96-9.61
Upgrade
Preferred Dividends & Other Adjustments
---0.020.15
Upgrade
Net Income to Common
-69.63-75.52-51.51-22.99-9.76
Upgrade
Shares Outstanding (Basic)
292624120
Upgrade
Shares Outstanding (Diluted)
292624120
Upgrade
Shares Change (YoY)
8.55%7.60%99.06%4975.15%0.32%
Upgrade
EPS (Basic)
-2.44-2.87-2.10-1.87-40.31
Upgrade
EPS (Diluted)
-2.44-2.87-2.10-1.87-40.31
Upgrade
Free Cash Flow
-71.2-56.92-39.32-27.58-7.86
Upgrade
Free Cash Flow Per Share
-2.49-2.16-1.61-2.24-32.44
Upgrade
EBITDA
-74.31-81.31-53.17-23.01-8.89
Upgrade
D&A For EBITDA
0.280.10.070.020
Upgrade
EBIT
-74.6-81.41-53.24-23.02-8.89
Upgrade
Updated Feb 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q